Cidara Therapeutics Inc (CDTX) stock forecast · rev $1.3M
Cidara Therapeutics Inc (CDTX) is a biotechnology company listed on US.
This CDTX forecast page states what the cached financials imply — not a price target and not a guarantee. Cidara Therapeutics Inc outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported CDTX revenue for 2024-12-31 was $1.3M. Net income was -$169.8M. Revenue was down 94.5% from 2023-12-31 to 2024-12-31. CDTX currently screens at market cap $6.96B.
The near-term path: Revenue was down 94.5% from 2023-12-31 to 2024-12-31. A forecast that ignores that change is just a story.
CDTX currently screens at market cap $6.96B. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next CDTX 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the CDTX stock page.
Not investment advice.